Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy.

Biomaterials science - 9 Nov 2021

Huang Guojun, Chen Qi, Hu Jiawei, Mao Jianming, He Yunhong, Bai Hongzhen, Tang Guping

Abstract excerpt

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treated patients ultimately develop disease progression, about 50% of which are involved in the emergence of a p.Thr790Met (T790M) mutation acquiring drug resistance. In order to solve the aforementioned problem, a therapeutic nanoparticles DGA is developed to overcome EGFR-T790M resistance via downstream anti-apoptotic signal transduction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Chitosan
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to MicroRNAs

Share to Nanoparticles

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 34751282
DOI: 10.1039/d1bm01133b

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy.PMID 34751282Read ↗

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer.Semantic proximity Read ↗

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.Semantic proximity Read ↗

Nanomedicine Strategies for Management of Drug Resistance in Lung CancerSemantic proximity Read ↗

Ultrasound-propelled liposome circumvention and siRNA silencing reverse BRAF mutation-arised cancer resistance to trametinib.Semantic proximity Read ↗

CNTs as Excellent Adjuvants for Anticancer Therapeutic Strategies and Cancer Diagnosis: A Plethora of Laboratory Studies versus Few Clinical Trials and Still No Clinical ApplicationSemantic proximity Read ↗

Advancements in gene therapy for lung cancer: from genetic insights to clinical applicationsSemantic proximity Read ↗

Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer.Semantic proximity Read ↗

BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation.Semantic proximity Read ↗

Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat.Semantic proximity Read ↗

Inhaled Gold Nano‐Star Carriers for Targeted Delivery of Triple Suicide Gene Therapy and Therapeutic MicroRNAs to Lung Metastases: Development and Validation in a Small Animal ModelSemantic proximity Read ↗

Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.Semantic proximity Read ↗

The Advancement in Magnetic Nanoparticles for the Diagnosis of Lung Cancer and Its MonitoringSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.